Table 4.
multivariable linear mixed effects regression model for the variation of total cholesterol after the switch from a PI- to an INI-containing regimen
| Estimate mg/dL |
SE | p value | |
|---|---|---|---|
| Female vs male | 4.26 | 2.26 | 0.061 |
| Age (x one yrs more) | 0.07 | 0.10 | 0.502 |
| Baseline cholesterol (x 1 unit more) | 0.80 | 0.02 | <0.0001 |
| Statins utilization yes vs no | –4.13 | 2.42 | 0.089 |
| Concomitant TDF interruption | 9.52 | 2.75 | 0.0006 |
| Time* | –1.66 | 2.25 | 0.461 |
| *ATVub vs ATV | 6.52 | 3.42 | 0.057 |
| *DRV vs ATV | –0.35 | 3.55 | 0.920 |
| *LPV vs ATV | –9.16 | 3.43 | 0.008 |
| *fAPV vs ATV | –21.59 | 4.34 | <0.0001 |
Note: *The estimates refer to parameters associated to the interaction between PIs and the time unit inserted in the model which is 6 months.
Abbreviations: SE, standard error; yrs, years; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; TDF, tenofovir disoproxil fumarato; PIs, protease inhibitors; INI, integrase inhibitors.